InvestorsHub Logo
Followers 0
Posts 82
Boards Moderated 0
Alias Born 04/30/2015

Re: None

Sunday, 02/19/2017 8:40:44 AM

Sunday, February 19, 2017 8:40:44 AM

Post# of 80490
I criticized Ariad Pharmaceuticals (ARIA) for jacking up the price of Iclusig and questioned the sanity of those who believe the lung cancer drug brigatinib is anything more than a me-too late comer. Still, Ariad's share price almost doubled in value in 2016, mainly on takeout speculation. Ouch! My grade: Incomplete (because I still don't believe Ariad will be acquired.)
- Adam Feuerstein, Dec. 22, 2016

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.